William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
Options Market Statistics: Palantir Shares See Volatility Ahead of Earnings; Options Pop
Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress
Larimar Therapeutics | 10-Q: Q1 2025 Earnings Report
Larimar Therapeutics Options Spot-On: On April 30th, 51,651 Contracts Were Traded, With 7,659 Open Interest
Express News | Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports First Quarter 2025 Financial Results
Express News | Larimar Therapeutics Q1 Operating Expenses USD 31.188 Million
Larimar Therapeutics 1Q Loss/Shr 46c >LRMR
Press Release: Larimar Therapeutics Reports First Quarter 2025 Financial Results
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia
Promising Developments and Financial Strength Support Buy Rating for Larimar Therapeutics
JonesTrading Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $10
Truist Financial Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
Larimar Therapeutics Should Be Bought on Weakness, Says Citi
Express News | Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $10
Larimar Therapeutics Analyst Ratings
Express News | Larimar Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $16 From $15